icon-    folder.gif   Conference Reports for NATAP  
  22nd Conference on Retroviruses and
Opportunistic Infections
Seattle Washington Feb 23 - 26, 2015
Back grey_arrow_rt.gif
Efavirenz Use Is Not Associated With Increased Risk of Neuropsychological Impairment
  Reported by Jules Levin
CROI 2015 Feb 23-26, Seattle, WA
Download the PDF here
Sean B. Rourke1,2,3 | John Gill4,5 | Anita Rachlis3,6 | Colin Kovacs7 | Gordon Arbess2 | Jason Brunetta7 | Adriana Carvalhal2,3 | Ron Rosenes1 | Robert Reinhard1 | Tsegaye Bekele1 | OHTN Cohort Study Team
1. The Ontario HIV Treatment Network, Toronto, Ontario, Canada
2. St. Michael's Hospital, Toronto, Ontario, Canada
3. University of Toronto, Toronto, Ontario, Canada
4. Alberta Health Services, Calgary, Alberta, Canada
5. University of Alberta, Calgary, Alberta, Canada.
6. Sunnybrook Hospital, Toronto, Ontario, Canada
7. Maple Leaf Medical Clinic, Toronto, Ontario, Canada.
(Melbourne/2014) Efavirenz Not Tied to Neurocognitive Impairment in Large Single-Center Study....http://www.natap.org/2014/IAC/IAC_30.htm
(CROI 2013) Long-Term Efavirenz Use is Associated with Worse Neurocognitive Functioning.....http://www.natap.org/2013/CROI/croi_39.htm
CROI: Neurocognitive Decline is Associated with Antiretroviral Concentrations in Cerebral Spinal Fluid and Blood (EFV, TDF) - (03/13/15)

"TLE (EFV regimen) was associated with greater risk of incident NCI over 96 weeks than ZLN (nevi rapine regimen)"
In our Canadian sample, current or past use of Efavirenz was not associated with an increased risk of neuropsychological impairment.
Our results are consistent with a recent study4 that reported no association between exposure to Efavirenz and increased risk of neurocognitive impairment.